Welcome to our dedicated page for Nuvation Bio SEC filings (Ticker: NUVB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nuvation Bio Inc. filings document the regulatory record of a public oncology company with Class A common stock listed on the New York Stock Exchange. The company's 8-K disclosures cover operating and financial results, material agreements, clinical and regulatory updates for taletrectinib and safusidenib, pipeline decisions involving its drug-drug conjugate program, and other material-event disclosures.
Proxy materials describe board elections, auditor ratification, executive compensation votes, shareholder voting procedures, and governance matters. Capital-structure filings identify the company's registered securities, including Class A common stock and historical warrant-related disclosures, while Form 25 records document removal of a warrant class from exchange listing and registration.
Nuvation Bio Inc. (NUVB) reported that Chief Scientific Officer Gary Hattersley exercised options for 100,000 shares of Class A Common Stock at an exercise price of $1.87 per share and sold 100,000 shares on the same date at a weighted-average price of $7.0924, under a Rule 10b5-1 trading plan dated December 4, 2025. Following the option exercise, he held 400,000 stock options directly, with the option expiring on February 27, 2034 and vesting 25% after one year from February 29, 2024 and monthly over the next 36 months, subject to continued service.
Nuvation Bio Inc. (NUVB) is the issuer for which officer Gary Hattersley filed a notice of proposed resale of restricted or control securities under Rule 144. The filing covers 100,000 shares of common stock, held via Morgan Stanley Smith Barney LLC, with an aggregate market value of $696,000.00 and an intended sale date of August 19, 2026, following an exercise of stock options for cash on the same date.
Nuvation Bio Inc. reported second quarter 2026 results with total revenue of $31.7 million, driven by $23.2 million in net product revenue from IBTROZI (taletrectinib) and $8.5 million from collaboration and license agreements. IBTROZI is described as the most prescribed ROS1 TKI in first-line and overall new ROS1+ NSCLC patient starts in 2026, with roughly 85% of about 160 new patients TKI‑naive.
The company recorded a net loss of $62.8 million, or $0.18 per share, as research and development expenses reached $30.7 million and selling, general and administrative costs were $42.6 million. Cash, cash equivalents and marketable securities totaled $661.0 million as of June 30, 2026, with an additional $36.5 million in net proceeds from a July 2026 exercise of the convertible senior notes overallotment option.
Nuvation highlighted updated long‑term Phase 2 data for investigational IDH1 inhibitor safusidenib and plans to expand its clinical program across IDH1‑mutant glioma. Multiple Phase 2 and Phase 3 trials continue for IBTROZI in ROS1+ NSCLC, including the global TRUST program, alongside the Phase 3 SIGMA study evaluating safusidenib as maintenance therapy in high‑risk IDH1‑mutant astrocytoma.
Nuvation Bio generated total revenue of $31.7 million for the quarter and $114.9 million for the six months ended June 30, 2026, driven by $41.7 million in net product revenue from IBTROZI and substantial collaboration and license income, including approximately $58.7 million of upfront license revenue from Eisai.
The company reported a six‑month net loss of approximately $57.4 million, improved from the prior‑year period as operating loss narrowed despite higher research and development and selling, general and administrative expenses. Cash, cash equivalents and marketable securities totaled $661.0 million, supported by a $250.0 million 0.75% Convertible Senior Notes offering and a $150 million revenue interest financing tied to U.S. IBTROZI sales. Management expects to continue incurring operating losses but believes existing capital will fund operations for at least 12 months.
Nuvation Bio Inc. reports that Chief Financial Officer Philippe Sauvage exercised employee stock options covering 40,000 shares of Class A common stock on July 15, 2026 through two transactions at exercise prices of $1.97 and $2.17 per share. Corresponding option positions were reduced, while the acquired shares are held directly. Footnotes state that the reported common share balance includes 1,458 shares purchased through the employee stock purchase plan on May 19, 2026, and describe option grants that vest 25% on the one-year anniversaries of October 7, 2024 and February 28, 2025 and monthly over the following 36 months, subject to continued service.
Nuvation Bio Inc. has fully closed a registered underwritten offering of $287.5 million aggregate principal amount of 0.75% Convertible Senior Notes due 2032, including a $37.5 million greenshoe exercised by underwriters.
The company expects net proceeds of about $277.6 million after fees. It used roughly $2.2 million of the greenshoe proceeds to purchase additional capped call transactions designed to lessen potential dilution or higher cash payments upon note conversion, and plans to deploy the remaining funds for general corporate purposes such as working capital, operating expenses, capital expenditures, and administrative costs.
Nuvation Bio Inc. completed an underwritten public offering of $250.0 million aggregate principal amount of 0.75% Convertible Senior Notes due 2032, with underwriters holding a 30‑day option to buy up to an additional $37.5 million of notes. The notes are unsecured, pay interest semiannually, and are convertible into cash, Class A common stock, or a combination, at the company’s election.
The initial conversion rate is 127.4941 shares per $1,000 of notes, implying a conversion price of about $7.84 per share, a 35.0% premium to the June 25, 2026 share price. Nuvation Bio estimates net proceeds of $241.2 million, used to fund $14.9 million of capped call transactions and to repay in full about $58.5 million under its senior secured loan agreement, with the balance for general corporate purposes.
Nuvation Bio is offering $250,000,000 aggregate principal amount of 0.75% Convertible Senior Notes due 2032. The notes bear interest at 0.75% per year, mature on July 1, 2032, and are convertible at an initial rate of 127.4941 shares per $1,000 (≈ $7.84 per share), subject to adjustment and conditional conversion mechanics.
The company expects net proceeds of approximately $241.2 million, intends to use proceeds to pay the $14.9 million capped call cost, repay in full the Loan Agreement obligations and for general corporate purposes, and will issue the notes in book-entry form with expected delivery around June 30, 2026.
Nuvation Bio Inc. proposes an offering of $200,000,000 principal amount of % Convertible Senior Notes due 2032. The notes bear cash interest payable semiannually, may be convertible into Class A common stock at an initial conversion rate (conversion price disclosed in the prospectus), and mature on July 1, 2032. Prior to April 1, 2032, conversions are conditional; after that date conversions are permitted at any time. The company may redeem the notes on or after July 6, 2029 if the Class A common stock trading thresholds are met. Net proceeds are expected to be used to pay capped call costs, repay the Loan Agreement and for general corporate purposes.
Nuvation Bio Inc. chief people officer Stacy Markel exercised stock options and sold shares in the company. On June 23, 2026, Markel exercised options for 34,620 shares at $1.74 per share and 90,380 shares at $1.87 per share, then sold 125,000 Class A common shares in an open-market transaction at a weighted-average price of $6.0255 per share, with trades ranging from $6.00 to $6.085, under a pre-arranged Rule 10b5-1 trading plan dated December 4, 2025. After these transactions, Markel directly holds 32,591 Class A common shares.